# Merlintrader Trading Pub

> Biotech catalyst news and analysis. FDA PDUFA tracker


## Posts

- [What Four Greenland Stocks Own: $CRML, $GRML, $GLND, $VEEE](https://www.merlintrader.com/what-four-greenland-stocks-own-crml-grml-glnd-veee/): After the US-Denmark security deal over Greenland, four US-listed names repriced. What Critical Metals, Greenland Mines, Greenland Energy and Twin Vee PowerCats actually own, from their SEC filings.
- [AI’s New Bottleneck Is Power: What Happens When the Constraint Moves From the GPU to the Megawatt?](https://www.merlintrader.com/ai-bottleneck-power/): The scarce resource increasingly deciding how much AI capacity can actually be deployed is electricity. GPUs, networking and models still matter, but the new economic question is how efficiently operators can turn secured megawatts into useful, billable compute. NVIDIA’s DSX platform and the newly launched AI Energy Management Alliance are attempts to make power itself programmable — inside the data center and, potentially, at the grid interface.
- [$MSOS $TLRY $CGC $ACB: Cannabis Reform Holds, but the Sector Splits](https://www.merlintrader.com/cannabis-september-2026-msos-tlry-cgc-acb/): From August’s DEA closing briefs to September’s developments: the U.S. medical framework survives a stay request, Congress delays part of the hemp restrictions, Germany raises new questions and Aurora battles Curaleaf. Meanwhile, company accounts are telling increasingly different stories.
- [Biotech Radar September 15, 2026: CNTB, BIVI, CRBP and ARMP — Asthma, Long COVID, Obesity and Phage Therapy](https://www.merlintrader.com/biotech-radar-september-15-2026-cntb-bivi-crbp-armp/): Biotech Radar: CNTB asthma data, BIVI Long COVID findings, CRBP obesity results and ARMP FDA designation, plus financing, diagnostics and medtech updates.
- [The Drone War Is Becoming an Industry: $ONDS, $RCAT, $DPRO and $AVAV Enter the Next Phase of Defense Autonomy](https://www.merlintrader.com/onds-rcat-dpro-avav-defense-autonomy-drone-industry/): How $ONDS, $RCAT, $DPRO and $AVAV are turning defense autonomy into an industry: orders, manufacturing, cash, dilution and the next execution tests.
- [Bloom Energy, FuelCell and Plug Power: behind the rally, three different approaches to the race for energy](https://www.merlintrader.com/bloom-fuelcell-plug-energy-rally-september-8-2026/): Bloom Energy, FuelCell and Plug Power: the rally, sector outlook, financials, contracts, liquidity and catalysts, with all three Stock Hubs.
- [Biotech Radar September 9, 2026: $ROIV, $BEAM, $UPB, $BMY](https://www.merlintrader.com/biotech-radar-september-9-2026/): Biotech Radar: $ROIV, $BEAM, $UPB and $BMY report clinical progress. Mosliciguat, BEAM-302, verekitug and arlo-cel: evidence and next steps.
- [$PL $RKLB $SATL $LUNR: Space Stocks After the Selloff](https://www.merlintrader.com/pl-rklb-satl-lunr-space-stocks-after-selloff/): Compare Planet Labs, Rocket Lab, Satellogic and Intuitive Machines: analyst targets, financial results and the next execution milestones after the selloff.
- [Biotech Radar: Evaluating $IONS, $STOK, $CLYM, $APVO](https://www.merlintrader.com/biotech-radar-evaluating-ions-stok-clym-apvo/): Merlintrader Biotech Radar · September 4, 2026 Biotech Radar — September 4, 2026: $IONS, $STOK, $CLYM & $APVO Lead an FDA, Dravet, IgAN and AML Tape Four companies sit at four different points on the biotech evidence ladder: Ionis has crossed an FDA finish line, Stoke has added four-year Dravet durability data ahead of a […]
- [Russell Quarterly IPO Additions, September 2026: The Full Preliminary List, With $QNT, $FRVO, $HAWK and $COAG as Worked Examples](https://www.merlintrader.com/russell-ipo-additions-september-2026/): FTSE Russell's September 2026 quarterly IPO addition list: 36 new tickers joining the Russell 1000, Russell 2000 and Russell Microcap indexes, with $QNT, $FRVO, $HAWK and $COAG as verified worked examples and primary sources for every name.
- [Late-Summer 2026 Cruises: Carnival, Royal Caribbean and Norwegian ($CCL $RCL $NCLH)](https://www.merlintrader.com/cruises-late-summer-2026-ccl-rcl-nclh-fall-winter-outlook/): Carnival, Royal Caribbean and Norwegian at the end of summer 2026: Q2 results, bookings, yields, fuel and fall/winter scenarios.
- [Late-Summer 2026 Rental Cars & Mobility: Avis, Hertz and Uber ($CAR $HTZ $UBER)](https://www.merlintrader.com/rental-cars-mobility-late-summer-2026-car-htz-uber/): Avis, Hertz and Uber at the end of summer 2026: fleet utilization, pricing, bookings, cash generation and fall/winter scenarios.
- [Late-Summer 2026 Hotels: Hilton, Marriott and Hyatt ($HLT $MAR $H)](https://www.merlintrader.com/hotels-late-summer-2026-hlt-mar-h-fall-winter-outlook/): Hilton, Marriott and Hyatt at the end of summer 2026: RevPAR, pipelines, fee growth, openings and the next-season investment setup.
- [Late-Summer 2026 Airlines: American, Delta and United ($AAL $DAL $UAL)](https://www.merlintrader.com/airlines-late-summer-2026-aal-dal-ual-fall-winter-outlook/): A late-summer 2026 operating scorecard for American, Delta and United: Q2 results, fuel risk, demand quality and the fall/winter outlook.
- [$SPCX, $RKLB, $FLY, $LUNR: Who Is Most Exposed to America’s 1,000-Launch Space Policy?](https://www.merlintrader.com/spcx-rklb-fly-lunr-us-1000-launch-space-policy/): America’s new space transportation policy targets more than 1,000 launches and reentries a year by 2030. SpaceX, Rocket Lab and Firefly are the clearest launch exposures; Intuitive Machines is the strongest lunar-logistics read-through. The policy is a strategic tailwind, not a contract or a funded revenue guarantee.
- [$TVTX vs $VERA: The Business That Already Exists vs the Upside That Could Become Enormous](https://www.merlintrader.com/tvtx-vs-vera-iga-nephropathy-stock-comparison/): Travere Therapeutics and Vera Therapeutics look like an easy pair to compare: both operate in rare kidney disease, both have major exposure to IgA nephropathy, and their flagship products will increasingly compete for attention from the same nephrologists. Yet investors are actually choosing between two almost opposite profiles.
- [You Are Not Holding a Stock, You Are Wearing Its Shirt: A Field Guide to Falling in Love With a Ticker](https://www.merlintrader.com/falling-in-love-with-a-ticker-investor-bias-field-guide/): Nobody plans it. You do some research, you buy a small position, and eleven months later you are defending a company at two in the morning. The seven people in every ticker feed, the dictionary of the smitten, the four bills, and a cold test in four questions.
- [$MSOS $TLRY $CGC $ACB: Inside the 274 Pages That Closed the Cannabis Rescheduling Record](https://www.merlintrader.com/cannabis-rescheduling-post-hearing-briefs-msos-tlry-cgc-acb/): Every party in the DEA rescheduling case filed on August 17. The Government asked for Schedule III; all six other filings asked that marijuana stay in Schedule I. What the 274 pages say, what the sector reported, and which dates are real.
- [Biotech Radar — August 15, 2026: $CAPR, $ABCL and $DFTX Lead a Week of FDA Turns, Clinical Wins and Hard Resets](https://www.merlintrader.com/biotech-radar-august-15-2026-capr-abcl-dftx/): Biotech Radar for Aug. 15, 2026: CAPR, ABCL and DFTX lead, plus TENX, SION, PDSB, FDA approvals, clinical data, earnings and biotech deals.
- [US Drone Tariffs Explained: The Six-Layer Supply Chain Map, With $RCAT, $ONDS, $AVAV and $LPTH As Worked Examples](https://www.merlintrader.com/us-drone-tariffs-2026-supply-chain-map/): The Section 232 proclamation of August 13, 2026 puts a 100 percent duty on imported drones from September 3, defers a 25 percent component tier to February 2027, and arrived on the same day export controls were loosened. A six-layer map of the supply chain, four worked examples and a five-question routine for reading the next announcement.
- [$BE, $CRWV, $NBIS And $OKLO: What The Second Quarter Revealed About The AI Power Boom](https://www.merlintrader.com/ai-power-q2-2026-be-crwv-nbis-oklo/): Three companies serving the same AI data centre demand reported three completely different quarters. Bloom Energy passed $1 billion of revenue and made a profit. CoreWeave doubled revenue and paid $640 million of interest. Nebius grew 454% and spent $5.66 billion on capacity. Meanwhile the nuclear names are down a third this year.
- [RKLB, ASTS, LUNR, RDW: Real Reversal or Dead Cat Bounce? Space & Defense After the Crash](https://www.merlintrader.com/rklb-asts-lunr-rdw-space-defense-reversal-2026/): Between late May and July 29, 2026, RKLB, ASTS, LUNR and RDW lost 60-75% of their value, then rallied 35-75% in seven sessions. Nine defense names beat and raised guidance. Real reversal, or dead cat bounce? The next earnings decide.
- [$NBIS, $MSFT, $BE and $ORCL: Nebius Vineland and the $17.4 Billion Microsoft Bet](https://www.merlintrader.com/nebius-vineland-data-center-nbis-microsoft/): The Nebius Vineland AI data center is already under construction while the amended site plan returns to a Planning Board hearing on August 17. Inside $NBIS: the $17.4 billion Microsoft contract, the Bloom Energy power redesign, Michael Burry's short, DA Davidson's cut to $175 and the August 12 earnings call.
- [$OKLO, $XE, $SMR and $IMSR: Four Advanced Nuclear Business Models, Compared](https://www.merlintrader.com/advanced-nuclear-stocks-compared-oklo-xe-smr-imsr/): Oklo, X-Energy, NuScale and Terrestrial Energy are usually traded as one theme. They are four different businesses. A comparison on business model, regulatory status, fuel enrichment, contracts and cash, with a reusable six-question triage tool.
- [Biotech Radar — August 5, 2026: $OBX, $ACRV and $URGN Lead a Broad Clinical and Capital-Markets Tape](https://www.merlintrader.com/biotech-radar-august-5-2026-obx-acrv-urgn/): Biotech Radar for August 5, 2026: $OBX, $ACRV and $URGN lead, with clinical, commercial and financing news across nine additional biotech names.
- [Biotech Radar July 29, 2026: PolyPid Gets Priority Review, Processa Resets Around VT-7208, TScan Starts Phase 3 — $PYPD $PCSA $TCRX](https://www.merlintrader.com/biotech-radar-july-29-2026-pypd-pcsa-tcrx/): PolyPid receives FDA Priority Review for D-PLEX100, Processa rebuilds around VT-7208 with a $200 million financing, and TScan begins pivotal Phase 3 execution.
- [Biotech Radar July 28, 2026: Kiniksa Rerates, Nautilus Pushes Voyager Shipments to Mid-2027 and Alkermes Expands Its Sleep Franchise — $KNSA $NAUT $ALKS](https://www.merlintrader.com/biotech-radar-july28-2026/): Today’s Radar separates a genuine commercial-plus-clinical rerating at Kiniksa from a material commercialization-timeline reset at Nautilus Biotechnology and a strong but more complex post-acquisition quarter at Alkermes. NeoGenomics and Mirion remain on the closing-bell watchlist, with results scheduled after the market closes.
- [$MSOS $TLRY $CGC $ACB: After the DEA Hearing, the Cannabis Trade Moves Into the Shadows](https://www.merlintrader.com/after-dea-hearing-cannabis-moves/): The courtroom has gone quiet, but the federal cannabis story is becoming more complicated—not less. Behind the August 17 deadline, investors are watching an unfinished tax rule, a dangerous court challenge and a Schedule II scenario that few traders appear prepared to discuss.
- [Biotech Radar July 27, 2026: Entera Bio ($ENTX), Freenome ($FRNM), Sarepta Therapeutics ($SRPT) and Legend Biotech ($LEGN)](https://www.merlintrader.com/biotech-radar-july27-2026/): Four biotech stories moved onto the radar for four very different reasons: a company-changing financing at $ENTX, a first commercial FDA approval at $FRNM, a planned leadership handoff at $SRPT and a sudden CEO departure at $LEGN.
- [Golden Dome Enters the Procurement Era: 108 Tracking Satellites, the FY2027 Funding Fight and What It Means for $LHX $RKLB $LMT $NOC](https://www.merlintrader.com/golden-dome-procurement-era/): Golden Dome is no longer only a presidential vision or a broad market narrative. Congress has begun writing oversight into law, billions are moving through missile-warning and tracking awards, and the next political battle is already forming around FY2027 funding, space-based interceptors, acquisition authority and the true cost of defending the U.S. homeland.
- [Cannabis News Today: DEA Rescheduling, U.S. Hemp and $ACB $TLRY $CRON $CGC](https://www.merlintrader.com/cannabis-news-today-dea-rescheduling-july25/): A complete cannabis-sector update: the federal hearing is over, but a decision is not imminent; Congress is split between legalization and an attempt to block rescheduling; industry political donations are rising; and a parallel court fight could delay the process. Meanwhile, Aurora Cannabis, Tilray Brands, Cronos Group and Canopy Growth are looking for company-specific catalysts that do not depend entirely on Washington.
- [Biotech Radar July 22, 2026: BridgeBio, Curis, Monopar and Others — $BBIO $CRIS $MNPR](https://www.merlintrader.com/biotech-radar-july22/): Six verified biotech developments published today: an accepted rare-disease NDA, updated PCNSL response data, the opening of a rolling Wilson-disease application, a positive brain-metastases imaging study, a Canadian ALS regulatory path and a $1.5 billion cell-therapy tools acquisition.
- [Why The Critical-Minerals Race Is Won In The Midstream, Not The Mine ($UAMY, $MP, $USAR, $TMC)](https://www.merlintrader.com/critical-minerals-midstream-explained-uamy/): A framework for reading the critical-minerals sector: why the real bottleneck is processing (the midstream), a four-question tool to triage any headline, with $UAMY as the worked example and $MP, $USAR and $TMC on the map.
- [Priority Review Vouchers Explained: How an FDA Approval Becomes $180-205 Million in Cash, With $RCKT and $DNLI as Worked Examples · $XBI $IBB](https://www.merlintrader.com/priority-review-voucher-explained-rckt-dnli-2026/): How Rare Pediatric Disease Priority Review Vouchers turn a single FDA approval into $180-205 million in non-dilutive cash - the mechanism explained, with $RCKT and $DNLI as worked examples.
- [Betting on the FDA: How Kalshi's Biotech Prediction Markets Work, and What They Mean for $XBI, $IBB and the Sector](https://www.merlintrader.com/kalshi-biotech-prediction-markets-fda/): Kalshi launched a pilot program on July 16, 2026, enabling trading on clinical trial outcomes and FDA decisions linked to biotech firms. This new prediction market offers a public price reflecting the probability of drug approval, but raises ethical concerns and potential manipulation risks due to limited participant knowledge and liquidity challenges.
- [The Cannabis Risk That Quietly Died in January: What It Means for $MSOS, $TLRY, $CGC and $ACB](https://www.merlintrader.com/cannabis-rescheduling-rider-january-2026/): Congress stripped the provision that would have defunded marijuana rescheduling — the House passed the clean bill 397-28 — and cannabis investors never priced it. Meanwhile the sector fell during the DEA hearing itself.
- [Biotech Radar July 17, 2026: Kalaris, REGENXBIO and Novartis — $KLRS $RGNX $NVS](https://www.merlintrader.com/biotech-radar-july17-2026/): A full three-company edition covering an early wet-AMD durability signal, a $100 million gene-therapy financing that materially resets per-share ownership, and a traditional FDA approval that raises the evidence standard across the increasingly competitive IgA-nephropathy market.
- [Why U.S. Defense Stocks Are Correcting: $LMT, $AVAV, $KTOS, $RCAT and the Full Merlintrader Stock-Hub Map](https://www.merlintrader.com/defense-stocks-correcting/): A U.S.-only defense report covering traditional primes, scaled defense-tech, high-beta drone and AI names, and national-security space companies already followed by Merlintrader. The central question is not whether military demand exists, but which companies can turn budgets and contract ceilings into funded backlog, margins and free cash flow per share.
- [Why Space Stocks Keep Falling: $RKLB, $ASTS, $PL, $LUNR and the July 2026 Reversal Map](https://www.merlintrader.com/space-stocks-keep-failing/): The space economy has not stopped growing, but its public-market proxies have lost scarcity, absorbed a wave of new securities and broken key technical support. This report separates the common sector shock from each company’s own risks and identifies what would have to change before the decline can credibly reverse.
- [Biotech Radar July 16, 2026: Gain Therapeutics, aTyr Pharma and Medicus Pharma — $GANX $ATYR $MDCX](https://www.merlintrader.com/biotech-radar-july16-2026/): Three biotech updates, three very different evidence problems: an early Parkinson’s disease signal moving toward Phase 2, a post hoc attempt to rescue a pulmonary sarcoidosis program after a missed Phase 3 endpoint, and an FDA-guided protocol optimization that may make a urology study faster and less expensive without yet proving efficacy.
- [Beyond Nvidia: The Physical AI Infrastructure Chain Behind Defense, Power and Critical Minerals — $BBAI $BE $MP](https://www.merlintrader.com/physical-ai-infrastructure-chain-defense-power-minerals/): The AI boom is no longer only a semiconductor and cloud-computing story. It is becoming a race for mission-ready software, deployable electricity and secure magnet supply. This report separates the common narrative from the very different financial realities of BigBear.ai, Bloom Energy and MP Materials.
- [Cannabis Rescheduling Hearing Final Wrap: What the Record Says for $ACB , $MSOS , $TLRY and $CGC](https://www.merlintrader.com/cannabis-rescheduling-hearing-final-wrap/): The July 15 testimony is over. There is no verdict, no vote and no broad Schedule III final rule yet. The hearing nevertheless clarified which parts of the government’s case survived, where the opposition created real legal risk and what investors should watch next.
- [Biotech Radar — July 15, 2026: Biogen and Ionis — Diranersen Lowers Tau, but CELIA Leaves Clinical Risk Unresolved ($BIIB, $IONS)](https://www.merlintrader.com/biotech-radar-july15-biogen-and-ionis/): Phase 2 CELIA produced one of the most intriguing tau signals yet seen in Alzheimer’s disease, but it did not settle the key issue: why did the lowest dose show the most persuasive cognitive benefit while higher doses failed to produce a stronger response?  $BIIB · $IONS Alzheimer’s · Tau · Antisense 
- [Biotech Radar July 14, 2026: Biogen ($BIIB), AstraZeneca ($AZN), GSK ($GSK) and Evotec ($EVO)](https://www.merlintrader.com/biotech-radar-july14-2026/): Merlintrader Biotech Radar Biotech Radar July 14, 2026: Biogen, AstraZeneca, GSK and Evotec — $BIIB, $AZN, $GSK, $EVO A deeper four-company edition covering an FDA delivery breakthrough in Alzheimer’s disease, a $1.5 billion lung-cancer licensing deal, a potentially treatment-changing organ-preservation strategy in rectal cancer, and a severe guidance reset that puts partnership economics under the […]
- [Gravity ($GRVY) Deep Dive 2026: The Ragnarok Cash Machine — One Franchise, 91 Regions, And A Cash Pile Near Its Market Cap](https://www.merlintrader.com/gravity-grvy-ragnarok-cash-machine/): Gravity ($GRVY) deep dive: verified Q1 2026 and FY2025 numbers, ~$400M cash and no debt against a ~$440M market cap, the Ragnarok launch engine, GungHo control, and the bull vs bear case. Educational, not advice.
- [Outlook Therapeutics ($OTLK): A Story — The World's Most-Used Eye Drug Is Not Approved for the Eye](https://www.merlintrader.com/otlk-outlook-a-story/): Off-label economics explained with Outlook Therapeutics ($OTLK): why the most-used wet AMD treatment costs $50 and is not approved, while approved alternatives cost twenty times more. FDA PDUFA July 29, 2026.
- [ImmunityBio ($IBRX): A Story — Why FDA Approval Is Only the Starting Line](https://www.merlintrader.com/ibrx-immunitybio-a-story/): An accessible three-act explainer using ImmunityBio ($IBRX) and its bladder-cancer drug Anktiva to show why FDA approval is only the starting line: the human stakes, the commercial launch curve, and who controls the company.
- [Oil Shock Returns: Trump, Iran and the Fed Put Wall Street’s Summer Rally Under Pressure $SPY](https://www.merlintrader.com/oil-shock-returns-july2026/): Macro & Markets Editorial Oil Shock Returns: Trump, Iran and the Fed Put Wall Street’s Summer Rally Under Pressure The renewed battle over the Strait of Hormuz is no longer only a geopolitical story. It is an inflation story, a bond-market story, a valuation story and—perhaps most importantly—a test of whether Washington can simultaneously pursue […]
- [Biotech Radar July 13, 2026: Sanofi, Guardant Health and Pharvaris](https://www.merlintrader.com/biotech-radar-july13-2026/): Biotech Radar July 13, 2026 $SNY $GH $PHVS Three-name biotech watch Biotech Radar July 13, 2026: Sanofi ($SNY), Guardant Health ($GH) and Pharvaris ($PHVS) Three distinct healthcare setups define today’s watch: a first-of-its-kind oncology delivery approval, a competitive read-through in blood-based colorectal-cancer screening, and an oral hereditary-angioedema program that has entered formal FDA review while […]
- [$MSOS $TLRY $CGC $ACB Cannabis Rescheduling Hearing Week 2 Wrap: Finn, the TBI and the July 15 Schedule III Deadline](https://www.merlintrader.com/cannabis-rescheduling-hearing-week2-wrap-july12/): Week two of the DEA marijuana rescheduling hearing: Dr. Kenneth Finn's testimony, the Tennessee Bureau of Investigation, the July 13-15 final stretch, and the non-binding path to a Schedule III Final Rule - and what it means for $MSOS, $TLRY, $CGC and $ACB.
- [Reusable Rockets Explained: The Launch Economics, $RKLB as the Worked Example, and What China's First Booster Catch Changes](https://www.merlintrader.com/reusable-rockets-launch-economics-explained/): A plain-English guide to the economics of reusable rockets: why refurbishing beats rebuilding, how cost-per-kg collapsed, where SpaceX ($SPCX), Blue Origin, China's Long March 10B and Rocket Lab ($RKLB) sit on the reuse ladder, a reusable triage for launch news, and what China's first booster catch does and doesn't change. Educational, not investment advice.
- [Why AI Needs Optics: The Optical Interconnect Stack Explained, With POET as the Worked Example](https://www.merlintrader.com/ai-optical-interconnect-explained-poet/): An educational guide to the AI optical interconnect stack - switch silicon, lasers, modulators, optical engines and modules - using POET Technologies (POET) as the highlighted optical-engine example.
- [Space stocks weakness: the SpaceX rotation, insider selling and the Planet Labs case](https://www.merlintrader.com/space-stocks-weakness-july-2026/): Why space stocks pulled back in July 2026: profit-taking after a huge run, capital rotating to the newly public SpaceX, insider selling at Rocket Lab, the Rocket Lab-Iridium deal and the company-specific Planet Labs case. Educational, no recommendations.
- [Biotech Radar — July 11, 2026: Chemomab, CervoMed and AtaiBeckley — $CMMB $CRVO $ATAI](https://www.merlintrader.com/biotech-radar-jul11-2026/): Today’s radar compares three very different catalyst structures: Chemomab’s proposed merger with Scipher Medicine and shift toward AI-guided rheumatoid arthritis development, CervoMed’s completed Phase 2a enrollment in nonfluent variant primary progressive aphasia, and AtaiBeckley’s completion of dosing in the VLS-01 Phase 2b Elumina trial ahead of a Q4 2026 topline readout.
- [Penguin Solutions Stock Deep Dive: The AI Factory Platform Company Behind Memory, HPC and Full-Stack Infrastructure](https://www.merlintrader.com/penguin-solutions-july2026-deepdive/): Penguin Solutions has moved from the old SMART Global Holdings identity into a more focused AI infrastructure story. The market is no longer looking at PENG as a simple memory-cycle name. It is looking at a company trying to sit at the intersection of accelerated compute, advanced memory, AI cluster software, deployment services and enterprise-scale AI factory buildouts.
- [Biotech Radar — July 8, 2026: Vertex’s $10B Crinetics Deal, Seres’ Microbiome Signal and OKYO’s FDA Phase 3 Pathway ($CRNX, $MCRB, $OKYO)](https://www.merlintrader.com/biotech-radar-crnx-mcrb-okyo-july-2026/): Biotech radar: Vertex to acquire Crinetics ($CRNX) for ~$10B, Seres ($MCRB) posts an early 80% Day 15 SER-155 signal in checkpoint-inhibitor enterocolitis, and OKYO ($OKYO) moves urcosimod to Phase 3 NEPTUNE after FDA Type D feedback.
- [Oil Shock and the Hormuz Premium: Why $CVX, $XOM and $OXY Are Back in Focus](https://www.merlintrader.com/oil-shock-hormuz-premium-cvx-xom-oxy/): Oil surged over 6% and energy stocks jumped after the U.S.-Iran framework broke down and Iranian oil sanctions returned. The Strait of Hormuz premium puts Chevron ($CVX), Exxon Mobil ($XOM) and Occidental ($OXY) back in focus.
- [$MSOS $TLRY $CGC $ACB: Cannabis Rescheduling Hearing Update After DEA Recess Order Shifts the July 9 Schedule](https://www.merlintrader.com/cannabis-hearing-coverage-july7/): The July cannabis trade is no longer about a simple “rescheduling soon” headline. It is about the administrative record being built inside the DEA hearing room: medical use, abuse potential, dependence profile, public-safety arguments, product-standardization attacks, impaired-driving concerns and the litigation path that may follow any final Schedule III decision.
- [Biotech Radar: $VANI, $PHVS, $TOVX — Three Catalyst Stories From GLP-1 Implants to HAE and Pancreatic Cancer](https://www.merlintrader.com/biotech-radar-july7-deepdive/): Today’s radar is not built around one single theme. It is built around three very different biotech catalyst profiles: a small-cap GLP-1 implant narrative, a cleaner late-stage rare-disease regulatory story, and a highly speculative oncology microcap with a real but very early dosing question.
- [Trump Media & Technology Group ($DJT) Deep Dive: Truth Social, Crypto Treasury, Truth.Fi and the TAE Fusion Merger](https://www.merlintrader.com/trump-media-technology-group-djt-deep-dive-2026/): Deep dive on Trump Media ($DJT) after Q1 2026: $871K revenue, -$405.9M net loss driven by crypto marks, 9,542 BTC treasury, the CEO change, the paused Truth Social spin-off and the pending ~$6B TAE Technologies fusion merger.
- [$WULF, $AVGO, $MU: AI Infrastructure Back in Focus as Data Centers Replace the Old Crypto-Mining Story](https://www.merlintrader.com/wulf-avgo-mu-ai-infrastructure-2026/): Deep dive on the July 2026 AI infrastructure trade: TeraWulf's $19B Anthropic data-center lease, Broadcom's Apple custom-chip extension through 2031, and Micron's AI-driven memory super-cycle. $WULF, $AVGO, $MU.
- [Biotech Radar — July 6, 2026: $PHVS, $AGEN, $IONS (FDA NDA Acceptance, MSS Colorectal Survival Data, Phase 3 Angelman Milestone)](https://www.merlintrader.com/biotech-radar-phvs-agen-ions-july-2026/): Biotech radar for July 6, 2026: Pharvaris ($PHVS) FDA NDA acceptance with an April 2027 PDUFA date, Agenus ($AGEN) three-year BOT+BAL survival data in MSS colorectal cancer, and Ionis ($IONS) Phase 3 pivotal enrollment complete in Angelman syndrome.
- [Biotech & Trading Glossary: PDUFA, FDA & Small Caps](https://www.merlintrader.com/biotech-trading-glossary/): 70+ biotech, small-cap, FDA and trading terms explained clearly: PDUFA date, CRL, cash runway, short squeeze, surrogate endpoint and more.
- [Cannabis Rescheduling Watch: Why the Anti-Schedule III Case Matters Before the DEA’s July 15 Deadline](https://www.merlintrader.com/cannabis-rescheduling-watch-july5/): The cannabis trade is not waiting for a simple headline. It is watching an administrative record being built in real time. The key question is not only whether marijuana can move from Schedule I to Schedule III, but whether the evidence supporting that move is strong enough to survive opposition, procedural scrutiny and possible litigation.
- [AI: the 10 hottest stocks of July 2026](https://www.merlintrader.com/ai-hottest-stocks-july2026/): Ten artificial-intelligence names, screened for momentum, chart position and base, with the genuine small/mid caps up top. For each one: a mini chart, a short explainer, the AI niche and the real analyst price targets with sources.
- [Defense: the 10 hottest stocks of July 2026](https://www.merlintrader.com/defense-10-hottest-stockst-july26/): Watchlist 2026 · Defense & Defense-Tech Drones Space Counter-UAS Momentum AVAV · KTOS · RKLB · LUNR · PL · DRS · KRMN · RCAT · UMAC · ONDS Defense: the 10 hottest stocks of July 2026 Ten small and mid-cap names across defense and defense-tech, screened for momentum, chart position and base. For each […]
- [Atlas Lithium ($ATLX) Deep Dive 2026](https://www.merlintrader.com/atlas-lithium-july2026-deepdive/): The junior developer aiming to bring the Neves hard-rock lithium project into production in Minas Gerais' "Lithium Valley": a fully paid processing plant already shipped to Brazil, offtake deals with Mitsui, Chengxin and Yahua — but also years of delays, heavy dilution and a CEO who controls 51% of the vote.
- [NANO Nuclear Energy ($NNE) Deep Dive 2026](https://www.merlintrader.com/nano-nuclear-energy-july2026-deepdive/): The microreactor developer aiming to become a fully integrated nuclear supply chain for the AI data-center era: pre-commercial technology, a large cash pile and a calendar of regulatory and test milestones.
- [$MVIS MicroVision: Small-Cap LiDAR Reawakens as Defense, Security and AI Robotics Become the New Battleground](https://www.merlintrader.com/microvision-defense-security-robotics/): MicroVision’s new Southeast Asia partnership adds another piece to a busy 2026 commercial reset, but the story remains a high-risk execution trade: stronger customer activity, broader LiDAR portfolio, still-small revenue, meaningful cash burn and visible financing risk.
- [Biotech Radar July 1, 2026: $CANF, $ABVX, $SXTP and $MODD Lead Today’s Catalyst Watch](https://www.merlintrader.com/biotech-radar-july1/): Today’s biotech tape is not built around one single mega-cap headline. It is a classic catalyst radar session: one small oncology name with a fresh Phase 2a survival signal, one late-stage inflammatory disease story with a major Phase 3/NDA setup but financing pressure, one infectious-disease micro-cap tied to babesiosis development, and one diabetes medtech name moving from clearance into real-world use.
- [DEA Cannabis Hearing Begins: Why Schedule III Still Matters for $TLRY, $CGC and $MSOS](https://www.merlintrader.com/dea-cannabis-hearing-begins-june29/): The market did not get a final ruling today. What it got is the start of a federal process that could decide whether the cannabis trade remains a narrow medical-only tax story or becomes a broader sector repricing catalyst.
- [Analyst Price Targets in Biotech: Why the Most Quoted Number Is Often the Least Useful One](https://www.merlintrader.com/analyst-price-targets-in-biotech/): A deeper, U.S.-focused Merlintrader editorial on how to read sell-side price targets in small and mid-cap biotech, why 12-month targets often fail as forecasts, and why binary events such as PDUFA dates, Phase 3 readouts and FDA advisory committees can turn the “average target” into a misleading comfort number.
- [Three Space Stories That Matter Now: $RKLB’s Iridium Shock, $ASTS’s August Launch Window, and Rocket Lab’s NASA Credibility Trade. $IRDM](https://www.merlintrader.com/space-stories-matter-now-jun29/): The public space sector just received a concentrated set of catalysts: Rocket Lab is trying to buy an operating satellite communications network, AST SpaceMobile has placed its next BlueBird batch on the launch calendar, and NASA has selected Rocket Lab for dedicated Sun/Earth science missions. Together, these updates show how the investable space trade is moving beyond launch hype and into infrastructure, networks, services, and execution.
- [Biotech Radar — June 29, 2026: Ipsen-Kartos M&A, $CAPR’s FDA AdCom and $REPL’s RP1 Resubmission](https://www.merlintrader.com/biotech-radar-jun29/): The biotech calendar is entering a dense FDA-driven window, with three Nasdaq-listed names standing out for very different reasons: a renal-disease PDUFA decision watch, a rare-disease cell therapy advisory committee, and an oncology BLA resubmission that has put accelerated approval back in focus.
- [Space Economy 2026: $ASTS vs $RKLB vs $SPCE vs $FJET — Four Business Models Compared](https://www.merlintrader.com/space-economy-2026/): Space Economy · $ASTS · $RKLB · $SPCE · $FJET Space Economy 2026: $ASTS vs $RKLB vs $SPCE vs $FJET — Four Business Models Compared A focused comparison of four publicly traded US space-economy names: satellite-to-phone connectivity ($ASTS), launch and space systems ($RKLB), suborbital tourism ($SPCE), and supersonic flight-testing / air-launch infrastructure ($FJET), after the […]
- [Russell 2026 Final Rebalance Radar: Best Post-Upgrade Stocks to Watch by Sector](https://www.merlintrader.com/russell-2026-final-rebalance-radar-best-post-upgrade-stocks-to-watch-by-sector/): A sector-by-sector operational screen of the June 2026 Russell reconstitution, focused on stocks that deserve attention after the index event because chart structure, post-rebalance volume, fundamentals, catalysts and analyst target references overlap.
- [Space Stocks Selloff: Why $PL, $LUNR, $SATL, $ASTS and RKLB Are Falling Together After June’s Rally](https://www.merlintrader.com/space-selloff-june2026/): The June space trade is no longer being priced stock by stock. Planet Labs, Intuitive Machines, Satellogic, AST SpaceMobile and Rocket Lab are being traded as one high-beta space basket — and the unwind has exposed the same pressure points across the sector: SpaceX gravity, ETF outflows, valuation resets, execution risk, launch cadence, defense-contract timing and profit-taking after a crowded rally.
- [Russell 2026 Biotech Watchlist: $UNCY, $GALT, $SPRB, $OVID and the Small-Cap Health Care Additions to Watch](https://www.merlintrader.com/russell-2026-biotech-watchlist/): RUSSELL 2026 PRELIMINARY LIST 87 HEALTH CARE ADDITIONS BIOTECH FOCUS Russell 2026 Biotech Watchlist: $UNCY, $GALT, $SPRB, $OVID and the Small-Cap Health Care Additions to Watch The June 2026 Russell reconstitution becomes effective after the U.S. market close on June 26, with the new index membership active from the June 29 open. Among the Health […]
- [$SPCX, $RKLB, $LMT: Space Defense Is Moving From Launch Hype to Military Infrastructure](https://www.merlintrader.com/space-defense-military-infrastructure/): SpaceX’s massive financing push, Rocket Lab’s record-setting rapid-response U.S. Space Force mission, and the SB-AMTI sensing architecture point toward a bigger market theme: the next phase of the space trade may be less about launch spectacle and more about military infrastructure, orbital resilience, sensor networks, and defense procurement.
- [Biotech Radar – $DFTX $ABSI $NVCT – June 24, 2026](https://www.merlintrader.com/biotech-radar-june24-dftx-absi-nvct/): Phase 3 clinical data, analyst coverage and an international licensing deal: three real, verified catalysts across DFTX, ABSI and NVCT.
- [HIVE Digital Technologies (Nasdaq/TSX: $HIVE): Bitcoin Mining, AI Infrastructure, Paraguay, Canada and the New Compute Trade](https://www.merlintrader.com/hive-digital-technologies-june2026-deepdive/): HIVE is no longer just a public Bitcoin miner. The company is trying to become a dual-engine digital infrastructure platform, using renewable-powered mining scale, GPU infrastructure and BUZZ HPC to participate in the AI compute boom. The opportunity is real enough to monitor closely, but the equity remains exposed to Bitcoin volatility, dilution, capex intensity and major execution risk.
- [Keel Infrastructure Corp. (Nasdaq/TSX: $KEEL): From Bitcoin Miner To AI Power Infrastructure — A High-Beta Data Center Pivot To Watch](https://www.merlintrader.com/keel-infrastructure-corp-jun2026-deepdive/): Keel Infrastructure is trying to transform the former Bitfarms platform into a North American AI/HPC data center and power infrastructure story. The market narrative is powerful, the asset base is strategically relevant, and the balance sheet has been strengthened — but the investment case still depends on execution, customer leases, capital discipline and proof that megawatts can become durable infrastructure cash flow.
- [FedEx (NYSE: $FDX) Earnings Preview: The Real-Economy Checkpoint and the FedEx Freight Spin-Off Test — $FDX / $FDXF / $UPS](https://www.merlintrader.com/fedex-earnings-preview-real-economy-checkpoint/): FedEx reports Q4 FY26 on June 23, just weeks after completing the FedEx Freight spin-off and two days before FedEx Freight’s first separate Q4 call. That makes this more than an earnings preview. It is a test of the post-spin FedEx story, the “One FedEx” operating model, freight-cycle normalization, logistics demand, oil exposure, e-commerce activity, cost discipline, and the market’s willingness to reward transportation restructuring after a strong run.
- [The AI Infrastructure Rally Faces Its Next Reality Check: Micron Earnings And The Memory Bottleneck Trade — $MU / $NVDA / $AVGO](https://www.merlintrader.com/infrastructure-rally-june2026/): Micron Technology is about to report earnings at a moment when the market is treating artificial intelligence less like a single-stock story and more like a full infrastructure cycle. Nvidia still sits at the center of the trade. Broadcom has become one of the clearest public vehicles for custom AI accelerators and AI networking. But Micron occupies a different and increasingly important layer: the memory and storage layer that determines whether AI systems can feed accelerators, sustain inference workloads, handle longer context windows and scale data-center token output efficiently.
- [The OpenAI-Anthropic IPO Wave Could Pull the Entire AI Infrastructure Trade Into Focus — Some Possible Protagonists: $VRT / $ETN / $CEG](https://www.merlintrader.com/openai-anthropic-ipo-wave-into-focus/): Why the expected public-market debuts of OpenAI and Anthropic could shift investor attention toward the listed companies powering data centers, grid expansion, cooling, nuclear energy, gas, networking and the physical backbone of artificial intelligence.
- [Accenture: AI Disruption, Bookings Pressure And The IT Services Repricing — $ACN](https://www.merlintrader.com/accenture-ai-disruption/): Accenture's Q3 FY2026 report was not an operational collapse. Revenue grew, EPS improved and free cash flow remained solid. But weaker Managed Services bookings, softer guidance, a sharp analyst repricing and renewed anxiety about agentic AI turned the quarter into a warning shot for the traditional IT services model.
- [AI Power Bottleneck Trade: $SEI, $WTS and $BE Beyond the Chip Story](https://www.merlintrader.com/ai-power-bottleneck-trade/): The AI trade has spent most of the last cycle worshipping at the altar of GPUs, networking chips and hyperscale cloud capex. That made sense. Without compute, there is no AI boom. But the market is now being forced to confront a less glamorous and potentially more durable question: what happens when the servers are ready, the capital is available, the customer demand is real, but the power is not?
- [Lockheed Martin, Northrop Grumman and RTX ($LMT $NOC $RTX): Why the U.S. Air Force CCA Awards Mark a New Phase in Defense AI](https://www.merlintrader.com/lockheed-northrop-rtx-defense-ai/): The U.S. Air Force has moved Collaborative Combat Aircraft from prototype momentum toward engineering, manufacturing development, production and software competition. General Atomics and Anduril won the airframe contracts, but Lockheed Martin, Northrop Grumman and RTX Collins Aerospace are now inside the mission autonomy software pool — making $LMT, $NOC and $RTX the public-market way to follow a defense-AI shift that could reshape airpower over the next decade.
- [AIRO Group (Nasdaq: $AIRO): Why the RQ-70 Drone Story Is Suddenly Back on the Radar](https://www.merlintrader.com/airo-group-june2026-deepdive/): AIRO Group is moving back into focus because its RQ-70 Dainn drone story combines several themes that investors are watching closely: long-range ISR, AI-enabled autonomy, GNSS-denied operations, NATO-aligned demand, European defense capacity and small-cap defense momentum.
- [Rackspace Technology (Nasdaq: $RXT): AMD’s 30MW AI Compute Deal, Riyadh Expansion and the 2028 Debt Wall](https://www.merlintrader.com/rackspace-technology-riyadh-expansion/): Rackspace has suddenly become one of the market’s most aggressive AI infrastructure turnaround stories: a definitive AMD agreement for 30 MW of AI compute, a regional headquarters in Riyadh, a 15% workforce reduction and a stock price that has moved faster than the balance sheet. The story is real. The execution risk is real too.
- [Micropolis Robotics (NYSE American: $MCRP): Physical AI Moves From Hype To City Streets](https://www.merlintrader.com/micropolis-robotics-abu-dhabi-agreement/): Micropolis AI Robotics announced a five-year Abu Dhabi agreement for autonomous urban cleaning systems, giving traders a fresh Physical AI and smart-city robotics catalyst. The news is attention-grabbing, but the stock remains a highly speculative early-stage robotics name with filing, financing and execution risks that should not be ignored.
- [Defence AI Watch #1: Grok, Iran and the Defence-AI Supercycle — PLTR, KTOS, BBAI and PDYN](https://www.merlintrader.com/defence-ai-watch-june2026/): The news hook is today’s new disclosure on Grok’s role in U.S. Iran operations: it does not just change the defence-AI narrative, it reinforces the central theme of this column — data, targeting, drones, intelligence and tactical autonomy are entering the real operational chain.
- [Airlines and Travel Stocks Rebound as Peace Deal Hopes Drag Oil Lower: Why $AAL, $UAL, $DAL and $CCL Are Back on the Radar](https://www.merlintrader.com/airlines-travel-stocks-rebound-june2026/): The travel trade is suddenly alive again. A preliminary U.S.-Iran agreement has pushed crude prices sharply lower, lifted risk appetite and brought airlines, cruise lines and tourism-linked stocks back into focus. The setup is not risk-free: the deal still has political loose ends, jet fuel remains volatile, and the airline industry is still working through one of the harshest cost shocks since the pandemic era. But the market has a simple reason to pay attention: lower oil can quickly change the narrative for every company that moves people.
- [Fed, Inflation and Oil: Why SPY Is Trading the Energy Shock Before the June FOMC](https://www.merlintrader.com/fed-inflation-oil-june16fomc/): The market is not only reacting to lower crude prices. It is repricing the inflation path, the Federal Reserve’s room for patience, and the durability of the equity rally just as the June 16–17 FOMC meeting begins.
- [The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question](https://www.merlintrader.com/truce-usa-iran-june2026/): To understand the weight of the diplomatic turn announced between June 14 and June 15, it is necessary to go back to late February 2026, when the United States and Israel launched a military campaign against Iran. From that point, the conflict turned the Strait of Hormuz from a latent geopolitical risk into a central variable for oil, gas, inflation, interest rates and global equity markets.
- [SpaceX IPO: Why $SPCX Could Reprice the Public Space Stock Narrative](https://www.merlintrader.com/spacex-ipo-reprice-sector/): SpaceX is not just another listing. A record IPO at a reported $1.75 trillion valuation would turn Elon Musk’s rocket, Starlink and AI platform into the first true public-market benchmark for the modern space economy, with possible indirect read-through effects for $RKLB, $LUNR, $PL and $SATL.
- [LILA $107M, HOOD $55M, NCLH $25M, IFF $20M and more: the 20 largest insider purchases of the last two weeks](https://www.merlintrader.com/insider-buys-mayjune2026/): Insider purchases — cash buys at market prices by those who know the company from the inside — are among the most closely watched signals by professional investors. They are not a guarantee, but when a CEO, a board member, or a 10% shareholder buys millions of dollars with their own money, something is worth examining.
- [Market Crossroads: SPY, Inflation, War Risk, Fed Rates and the Trump Factor](https://www.merlintrader.com/market-crossroads-june2026/): The U.S. market is no longer trading a single story. SPY is now sitting at the intersection of an oil shock, sticky inflation, a cautious Federal Reserve, geopolitical escalation and a tariff-heavy policy backdrop.
- [AI Drones and Counter-Drone Radar Are Back in Focus: $JFB and $MPTI Put the Defense Tech Trade on Watch](https://www.merlintrader.com/ai-drones-counter-drones-in-focus-june2026/): Fresh contract news from XTEND, the pending merger target of JFB Construction Holdings, and M-tron’s growing RF exposure to counter-drone radar programs highlight a broader trader theme: autonomous defense systems are no longer a futuristic niche, but an increasingly active procurement lane.
- [Brand Engagement Network (Nasdaq: $BNAI): From January Spike to a Broader AI Execution Story](https://www.merlintrader.com/brand-engagement-networdk-june2026-deepdive/): BNAI has added new corporate events since the January squeeze — a pending Cataneo acquisition, an Accelevate investment, Q1 liquidity improvements and continued international AI expansion. The story is more developed, but the stock remains speculative, thin, headline-sensitive and vulnerable to violent swings.

## Pages

- [Decoy Therapeutics ($DCOY): Pan-Filovirus Research Opens a New Development Path](https://www.merlintrader.com/decoy-therapeutics-dcoy-stock-hub/): Decoy Therapeutics ($DCOY): new Ebola and Marburg in vitro data, the proposed FDA Animal Rule path, cash, milestone warrants and funding risks.
- [Celldex ($CLDX) Stock Hub: Barzolvolimab Meets Key Phase 3 CSU Endpoints](https://www.merlintrader.com/celldex-therapeutics-cldx-stock-hub/): Celldex ($CLDX) reports positive EMBARQ-CSU phase 3 results. Explore barzolvolimab data, the 2027 BLA plan, cash, dilution and remaining risks.
- [Longeveron ($LGVN) Stock Hub: ELPIS II Miss and the Funding Reset](https://www.merlintrader.com/longeveron-lgvn-stock-hub/): Longeveron ($LGVN): ELPIS II results, cash runway, conditional financing, dilution, Nasdaq compliance and the remaining laromestrocel pipeline.
- [Amneal ($AMRX) Stock Hub: Lanreotide Approval, Kashiv and Cash Flow](https://www.merlintrader.com/amneal-pharmaceuticals-amrx-stock-hub/): AMRX Stock Hub: FDA-approved lanreotide, Kashiv biosimilars, cash flow, debt, dilution, catalysts and risks. Primary-source analysis updated September 19, 2026.
- [PMVP Stock Hub — PMV Pharmaceuticals: rezatapopt, PYNNACLE ovarian data and the Q1 2027 NDA](https://www.merlintrader.com/pmv-pharmaceuticals-pmvp-stock-hub/): PMV Pharmaceuticals ($PMVP) stock hub: rezatapopt pivotal PYNNACLE ovarian data at 46% ORR on 76 patients, the September 2026 financing and its resettable warrants, and the accelerated-approval NDA guided for Q1 2027.
- [Biodexa ($BDRX) Stock Hub: Funding the Next eRapa Milestones](https://www.merlintrader.com/biodexa-pharmaceuticals-bdrx-stock-hub/): Biodexa $BDRX: September warrant financing, eRapa Serenta Phase 3, bladder-cancer data, cash needs and dilution risks in one research hub.
- [Space Launch Calendar: the Next 20 Launches](https://www.merlintrader.com/space-launch-calendar/): Track the next 20 space launches with mission, rocket, operator, launch site and status. A dynamic calendar with operator filters and local times.
- [Space, Defense & AI Event Calendar 2026–2027](https://www.merlintrader.com/space-defense-ai-event-calendar/): Merlintrader • Event Radar Space, Defense & AI: the events that can move the narrative A focused calendar of major conferences, industry summits, government-facing events and selected company watchpoints across space, defense and artificial intelligence. The goal is not to list everything: it is to flag the dates most likely to produce contracts, product roadmaps, […]
- [Scholar Rock ($SRRK) Stock Hub: ISEMBYLD Wins FDA Approval — Can the SMA Launch Build the Next Myostatin Franchise?](https://www.merlintrader.com/scholar-rock-srrk-stock-hub/): Scholar Rock $SRRK Stock Hub after FDA approval of ISEMBYLD: SAPPHIRE data, U.S. launch, cash, debt, dilution, FSHD and SRK-439 pipeline, global regulatory path, catalysts and risks.
- [Trulieve ($TRLV) Stock Hub: Added to the S&P Total Market and S&P Completion Indices](https://www.merlintrader.com/trulieve-trlv-stock-hub/): Trulieve $TRLV Stock Hub: medical operations, Harvest separation, Q2 cash flow, debt, tax exposure and the next catalysts after the NYSE listing.
- [Scribe Therapeutics ($SCTX) Stock Hub: a CRISPR Epigenetic Silencer Reaches the Clinic With Cash Into 2029](https://www.merlintrader.com/scribe-therapeutics-sctx-stock-hub/): Scribe Therapeutics ($SCTX) is dosing STX-1150, a CRISPR epigenetic silencer of PCSK9, in a first-in-human Phase 1. Cash into H1 2029, $25.7M from CIRM, first human data guided for H1 2027.
- [Inventiva ($IVA) Stock Hub 2026: NATiV3 Completed Its Last Patient Visit, Lanifibranor Topline Confirmed For Q4 2026, And The Financing Was Built For That Date](https://www.merlintrader.com/inventiva-iva-stock-hub/): Inventiva ($IVA) stock hub: the last patient in the NATiV3 Phase 3 completed the final 72-week visit on September 2, 2026, with 1,009 main-cohort and 410 exploratory-cohort patients; topline results are expected in Q4 2026. Cash and deposits of EUR 233.9M at June 30, 2026, EUR 75M of new secured bonds, the Tranche 3 warrants and every other instrument, dated and sourced. Educational research, not investment advice.
- [Nyxoah ($NYXH) Stock Hub 2026: ACCCESS Meets Both Primary Endpoints With a 77.2% Responder Rate, Opening the U.S. Door to CCC Patients](https://www.merlintrader.com/nyxoah-nyxh-stock-hub/): Nyxoah ($NYXH) stock hub: the ACCCESS U.S. pivotal study met both co-primary endpoints, 77.2% AHI and 87.7% ODI responder rates with zero device-related serious adverse events, and a PMA supplement is in preparation. EUR 97.8 million of cash, 101.8 million shares, a convertible bond, an Inspire patent case and a CEO search. Educational research, not investment advice.
- [Attovia Therapeutics ($ATTO) Stock Hub 2026: ATTO-1310 Shows Preliminary Clinical Proof of Concept in Itch, Complete Phase 1b Data Expected in Q4 2026, Cash Funded Into 2030](https://www.merlintrader.com/attovia-therapeutics-atto-stock-hub/): Attovia Therapeutics ($ATTO) stock hub: a single dose of the anti-IL-31 biologic ATTO-1310 was followed by rapid itch relief in chronic pruritus and high-itch atopic dermatitis in a 52-patient Phase 1b, complete data are expected in Q4 2026, two Phase 2 studies are planned for 1H 2027, and the $332.4 million IPO of August 2026 is stated to fund operations into 2030. Every figure sourced and dated. Educational research, not investment advice.
- [Merlintrader Stock Hubs: the complete map, sector by sector](https://www.merlintrader.com/stock-hubs/): Merlintrader Research Merlintrader Stock Hubs: the complete map A stock hub is the home page of a single company: what it does, where the programme or the contract stands, how much cash the latest filing reports, which dates can change the picture and where the risk sits. Every hub starts here, by sector or by […]
- [aTyr Pharma ($ATYR) Stock Hub 2026: What Does The FDA Protocol Response Change For The Efzofitimod Rebuild?](https://www.merlintrader.com/atyr-pharma-stock-hub/): aTyr is rebuilding its lead program after EFZO-FIT failed its Phase 3 primary endpoint. The new thesis is narrower: chronic symptomatic pulmonary sarcoidosis with restrictive lung disease, FVC as a prospective primary endpoint, 5 mg/kg dosing every three weeks, and a new global Phase 3 protocol now awaiting FDA feedback by mid-September 2026. The post hoc signal is scientifically interesting, but the company still faces regulatory, financing, Nasdaq-compliance and prospective-validation risk.
- [Belite Bio ($BLTE) Stock Hub: Tinlarebant Filed in Japan Under Sakigake, With a February 2027 PDUFA Ahead](https://www.merlintrader.com/belite-bio-blte-stock-hub/): Merlintrader Stock Hub · Biotech / Inherited retinal disease · Updated September 17, 2026 Priority ReviewPDUFA Feb 12, 2027Oral RBP4 antagonistNo approved therapy in STGD1 NASDAQ: $BLTE Belite Bio ($BLTE) Stock Hub: Tinlarebant Filed in Japan Under Sakigake, With a February 2027 PDUFA Ahead Belite Bio submitted a new drug application for tinlarebant to Japan’s […]
- [Alumis ($ALMS) Stock Hub 2026: Can Psoriasis Value Survive the LUMUS Miss?](https://www.merlintrader.com/alumis-alms-stock-hub/): Alumis ($ALMS) Hub: LUMUS missed overall, IFNGS-high subgroup, psoriasis NDA in Q4 2026, cash runway, dilution and the Phase 3 decision.
- [Kiniksa Pharmaceuticals (Nasdaq: $KNSA): Guidance Raised Twice In 2026, No Debt, And The Phase 3 That Has To Replace ARCALYST](https://www.merlintrader.com/kiniksa-pharmaceuticals-stock-hub/): Stock Hub 2026 · Biotech & Healthcare Commercial stageProfitableSingle-product concentrationExclusivity clock Nasdaq: $KNSA Kiniksa Pharmaceuticals (Nasdaq: $KNSA): Guidance Raised Twice In 2026, No Debt, And The Phase 3 That Has To Replace ARCALYST On July 28, 2026 Kiniksa raised its full-year ARCALYST revenue guidance for the second time this year, to $980–995 million, and reported […]
- [VisionWave ($VWAV): first revenue, and a 1-for-20 split to hold the Nasdaq listing](https://www.merlintrader.com/visionwave-holdings-vwav-stock-hub/): VisionWave Holdings ($VWAV) stock hub: three transactions announced between June 1 and August 31, 2026 and none completed, roughly $77.9 million of share consideration never issued, first revenue of $286,339 against a $25.8 million quarterly loss, $4.9 million of cash against $28.2 million of borrowings all classified as current, and a reverse split of up to 1-for-250 on the September 1 ballot. Educational research, not investment advice.
- [Protagonist Therapeutics ($PTGX) Stock Hub 2026: Two FDA Approvals, $275M Triggered by MIMRYLO—and the Royalty Test](https://www.merlintrader.com/protagonist-therapeutics-stock-hub/): Protagonist Therapeutics ($PTGX) research hub: MIMRYLO approval, VERIFY evidence, Takeda and J&J royalties, cash, pipeline, catalysts, dilution and risks.
- [Applied Digital ($APLD): 1,410 MW contracted](https://www.merlintrader.com/applied-digital-stock-hub/): Applied Digital ($APLD) Hub updated August 28, 2026: 1,410 MW contracted, 175 MW live, Q4 revenue quality, the capital stack, dilution and an explicit 3–24 month execution scorecard.
- [iBio ($IBIO) Stock Hub 2026: Single-Ascending-Dose Enrollment Completed, First IBIO-600 Interim Data Targeted for Q1 2027](https://www.merlintrader.com/ibio-inc-stock-hub/): iBio ($IBIO) research hub: IBIO-600 Phase 1, IBIO-610 Activin E data, cash runway, catalysts and the common-plus-pre-funded economic share base.
- [Oscar Health ($OSCR) Stock Hub: 2029 Targets and Thrive’s Share Distribution](https://www.merlintrader.com/oscar-health-oscr-stock-hub/): Oscar Health ($OSCR) stock hub: a record first half of 2026 with $9,527.4 million of revenue and a 75.0% medical loss ratio, a raised full year guidance whose arithmetic implies a loss-making second half, membership down 211,487 in a quarter, the September 16 Investor Day and the unsettled 2027 rulebook. Educational research, not investment advice.
- [Verrica Pharmaceuticals ($VRCA) Stock Hub 2026: YCANTH Demand Up 46%, COVE-2 Enrollment Complete With Topline Data Pulled Forward To Q1 2027](https://www.merlintrader.com/verrica-vrca-stock-hub/): $VRCA stock hub: COVE-2 enrollment complete with topline data guided to Q1 2027, $11.2M of cash and a going-concern statement, the $27.5M chairman credit facility, VP-315 Phase 2 data and the full catalyst map. Every figure sourced and dated.
- [Critical Metals ($CRML) Stock Hub: What Does A US$1.85 Billion Romanian Refinery Model Actually Commit To? • Editorial review Sep 17, 2026](https://www.merlintrader.com/critical-metals-crml-stock-hub/): Critical Metals ($CRML) stock hub: the Tanbreez rare-earth project in Greenland, the Wolfsberg lithium project in Austria, the European Lithium scheme with its new exchange-ratio collar, audited FY2025 accounts with a going-concern disclosure, and no mineral reserve. Every figure sourced and dated.
- [Candel Therapeutics ($CADL) Stock Hub 2026: Can Manufacturing Validation Clear The Way For The Q4 Prostate BLA?](https://www.merlintrader.com/candel-therapeutics-stock-hub/): Candel Therapeutics stock hub: a 745-patient phase 3 in localized prostate cancer published in The Lancet Oncology, a BLA planned for Q4 2026, the AURORA pivotal in NSCLC, $201.6 million of cash and a $100 million payment contingent on FDA approval.
- [Spyre Therapeutics ($SYRE) Stock Hub: SPY003 completes the SKYLINE Part A monotherapy readouts](https://www.merlintrader.com/spyre-therapeutics-syre-stock-hub/): Spyre Therapeutics ($SYRE) stock hub: SPY001 and SPY002 Part A induction data from the Phase 2 SKYLINE trial, the August 25 SKYWAY rheumatoid arthritis result that did not meet the company's internal bar, SPY003 expected in September, $1,145.3 million of cash with runway into the second half of 2029 and a $500 million at-the-market programme still undrawn. Educational research, not investment advice.
- [Anavex ($AVXL): PVG Files Presentation and Transcript Ahead of September 24 Meeting](https://www.merlintrader.com/anavex-avxl-stock-hub/): Anavex Life Sciences ($AVXL) stock hub: the European marketing application withdrawn in March 2026, the chief executive terminated for cause in April, two unfiled quarterly reports and a live Nasdaq deficiency, the contested board vote of September 24, and $118.3 million of cash with no debt. Educational research, not investment advice.
- [RenovoRx (Nasdaq: $RNXT) Stock Hub 2026: a Fully Enrolled Phase III, a 51% Extraction Ratio and the Milestone Warrants That Revenue Would Destroy](https://www.merlintrader.com/renovorx-rnxt-stock-hub/): RenovoRx ($RNXT) stock hub: the Phase III TIGeR-PaC trial fully enrolled with 78 of 86 events, the August 2026 peer-reviewed PK/PD publication, record quarterly revenue of $909,000 with raised guidance, $9.5 million of cash with no debt, and the milestone warrants a $1.5 million quarter would extinguish. Educational research, not investment advice.
- [BridgeBio Pharma ($BBIO) Stock Hub 2026: What Does The Most-Favored-Nation Agreement Change For Attruby, And What Do The Two PDUFA Dates Decide?](https://www.merlintrader.com/bridgebio-pharma-bbio-stock-hub/): BridgeBio Pharma ($BBIO) stock hub: the Attruby launch curve from $2.9M to $222.4M a quarter, $2.51 billion of convertible notes, $879.4 million of royalty obligations, negative shareholders equity and the PDUFA dates of November 27, 2026 and May 8, 2027.
- [Biomea Fusion (Nasdaq: $BMEA) Stock Hub 2026: COVALENT-211 Fully Enrolled, $35.2 Million of Cash and a December 20 Warrant Test](https://www.merlintrader.com/biomea-fusion-bmea-stock-hub/): Biomea Fusion ($BMEA) stock hub: COVALENT-211 fully enrolled on August 24, 2026, $35.2 million of cash against a going-concern statement, 51.0 million potential new shares, the BMF-650 readout window and every catalyst on the map. Educational research, not investment advice.
- [Fulcrum Therapeutics (Nasdaq: $FULC) Stock Hub 2026: What Does The Slate Medicines Reverse Merger And A $270 Million Cash Dividend Mean For Shareholders?](https://www.merlintrader.com/fulcrum-therapeutics-fulc-stock-hub/): Fulcrum Therapeutics ($FULC) stock hub: the Slate Medicines reverse merger signed on August 16, 2026, the cash dividend defined as net cash above $20.3 million and estimated at $270.0 million, the $245 million concurrent placement, $318.8 million of cash at June 30, 2026 and the full catalyst map. Educational research, not investment advice.
- [Amarin (Nasdaq: $AMRN) Stock Hub 2026: $314.6 Million Of Cash And No Debt Against A $297.2 Million Market Value, After The Supreme Court Ruling And The Recordati Model](https://www.merlintrader.com/amarin-amrn-stock-hub/): Amarin ($AMRN) stock hub: the June 2026 Supreme Court skinny-label decision, the Recordati licence across 59 countries, second-quarter 2026 revenue of $42.2 million, $314.6 million of cash with no debt, and every catalyst on the map. Educational research, not investment advice.
- [Kopin ($KOPN): Revenue Up 51% as MicroLED and Sentinel Hit Milestones](https://www.merlintrader.com/kopin-corporation-kopn-stock-hub/): Kopin Corporation stock hub: second quarter 2026 revenue up 50.6 per cent to $12.73 million because partners and the government are funding the research, product revenue down 21.9 per cent in the half, a $3.50 million operating loss, $24.88 million of cash and a $19.7 million judgment under appeal, with every catalyst to 2027 sourced and dated.
- [Uranium Energy ($UEC) Stock Hub: FY2026 Results September 29 Before the Open](https://www.merlintrader.com/uranium-energy-corp-uec-stock-hub/): Uranium Energy Corp stock hub: Burke Hollow in production since April 2026, 32,195 pounds produced in the third quarter of fiscal 2026 at $54.61 a pound, $488 million of cash and no debt, 1,456,000 pounds of unhedged uranium, no S-K 1300 reserves, and every catalyst to 2027, with every figure sourced and dated.
- [Uber Technologies ($UBER): €4.5 Billion Bond Offering and Aurora Stake Sale](https://www.merlintrader.com/uber-technologies-uber-stock-hub/): Uber transacted $58.022 billion in the second quarter of 2026 and spent $70 million on property and equipment. How the marketplace works, the three segments, the metric change, the $1.8 billion VAT file and what the filings really say about autonomous vehicles.
- [Hyatt Hotels ($H) Stock Hub: A Long-Term Loyalty Partnership With Delta, and Q3 Results Set for October 29 • Updated Sep 21, 2026](https://www.merlintrader.com/hyatt-hotels-stock-hub/): Stock Hub 2026 · Travel & Hotels Premium-focused platformHotel RevPAR +5.9%Pipeline 154K roomsDual-class governance NYSE: $H Hyatt Hotels ($H) Stock Hub: A Long-Term Loyalty Partnership With Delta, and Q3 Results Set for October 29 • Updated Sep 21, 2026 Hyatt announced a long-term collaboration between World of Hyatt and Delta SkyMiles on September 9, 2026, […]
- [Marriott International ($MAR) Stock Hub: A Three-Hotel Partnership in New Zealand and the First Ritz-Carlton Residences in Brooklyn • Updated Sep 21, 2026](https://www.merlintrader.com/marriott-international-stock-hub/): Stock Hub 2026 · Travel & Hotels Largest global systemRevPAR +3.4%Pipeline 629K roomsBonvoy >295M Nasdaq: $MAR Marriott International ($MAR) Stock Hub: A Three-Hotel Partnership in New Zealand and the First Ritz-Carlton Residences in Brooklyn • Updated Sep 21, 2026 Marriott is the largest of the three hotel platforms in this comparison: 1.814 million rooms, more […]
- [Hilton Worldwide ($HLT) Stock Hub: Hilton Expands Spark in the UK With Ten Signings and Its First Scottish Hotel • Updated Sep 21, 2026](https://www.merlintrader.com/hilton-worldwide-stock-hub/): Stock Hub 2026 · Travel & Hotels Asset-light fee platformRevPAR +3.9%Pipeline 541K rooms$13.4B debt NYSE: $HLT Hilton Worldwide ($HLT) Stock Hub: Hilton Expands Spark in the UK With Ten Signings and Its First Scottish Hotel • Updated Sep 21, 2026 Hilton signed ten Spark hotels in England and Wales on September 14, 2026 — 672 […]
- [Avis Budget Group ($CAR) Stock Hub: What Does a $292 Per-Unit Fleet Cost Do to the Economics? • Updated Sep 21, 2026](https://www.merlintrader.com/avis-budget-group-car-stock-hub/): Avis earned $0.98 a diluted share in Q2 2026 and lost $7.01 in the first half, on 35.3 million shares. Fleet economics, the $25.9 billion debt stack, the June refinancing and the Waymo pilot in Dallas.
- [Hertz Global Holdings ($HTZ) Stock Hub: Two Fleet Note Series Completed for $874 Million, and the December Cash Test • Updated Sep 21, 2026](https://www.merlintrader.com/hertz-global-holdings-htz-stock-hub/): $HTZ Stock Hub: Q2 GAAP profit versus adjusted loss, RPU/DPU sensitivity, August ABS funding, dilution and the planned December $200M cash repayment.
- [TG Therapeutics ($TGTX) Stock Hub: BRIUMVI Growth and the Next Subcutaneous Test](https://www.merlintrader.com/tg-therapeutics-tgtx-stock-hub/): TG Therapeutics ($TGTX) stock hub: BRIUMVI U.S. revenue of $227.7 million in the second quarter of 2026, full-year guidance raised to approximately $950 million, $612.3 million of cash against a $750 million secured term loan, and the subcutaneous Phase 3 topline due at year end.
- [CRISPR Therapeutics ($CRSP) Stock Hub: CASGEVY, CTX310 and the 2026 In Vivo Pipeline](https://www.merlintrader.com/crispr-therapeutics-crsp-stock-hub/): CRISPR Therapeutics ($CRSP) Stock Hub updated September 6, 2026: CTX310 one-year durability at ESC and in NEJM, CASGEVY sales and Vertex economics, $2.364 billion cash, 2031 converts, dilution map and the next guided catalysts.
- [Prime Medicine ($PRME): the first in vivo Prime Editing trial is recruiting in Auckland while the PM647 filing window runs to September 30](https://www.merlintrader.com/prime-medicine-stock-hub/): A source-led Prime Medicine Stock Hub covering PM577a, PM647, PM359, Prime Editing, the going-concern disclosure, cash runway, dilution, competition and 2026–2027 catalysts.
- [Arcturus Therapeutics ($ARCT) Stock Hub: ARCT-810 Phase 2 Update Set for September 23](https://www.merlintrader.com/arcturus-therapeutics-arct-stock-hub/): Arcturus Therapeutics stock hub: the CSL Seqirus termination and returned KOSTAIVE rights, the Thermo Fisher Phase 3 collaboration, ARCT-032 cystic fibrosis data, the ARCT-810 OTC readout due this quarter, and $191.5 million of cash with no debt, from the 10-Q filed August 6, 2026.
- [Beam Therapeutics ($BEAM) Stock Hub: BEAM-302 ERS Data, Durability, Safety and Pivotal Development](https://www.merlintrader.com/beam-therapeutics-stock-hub/): BEAM-302 September 8, 2026 ERS data: biomarker durability, hepatic safety and pivotal development. Clinical findings and evidence limitations.
- [Sana Biotechnology ($SANA) Stock Hub 2026: Runway, SC451 and SG293](https://www.merlintrader.com/sana-biotechnology-sana-stock-hub/): SANA stock hub: what the Q2 $93.3M equity raise actually changed, $160.5M cash, mid-2027 runway, going-concern warning, dilution, SC451 and SG293 catalysts, and a modelled Q1-Q2 2027 financing window.
- [Norwegian Cruise Line ($NCLH) Stock Hub: Great Tides Opens at Great Stirrup Cay, With a New Pier for Two Ships at Once • Updated Sep 21, 2026](https://www.merlintrader.com/norwegian-cruise-line-holdings-stock-hub/): Stock Hub 2026 · Travel & Cruise July guidance reducedLeverage 5.3xDestination investmentCosts improving NYSE: $NCLH Norwegian Cruise Line ($NCLH) Stock Hub: Great Tides Opens at Great Stirrup Cay, With a New Pier for Two Ships at Once • Updated Sep 21, 2026 Great Tides Waterpark opened on September 4, 2026 on Great Stirrup Cay, nearly […]
- [Royal Caribbean ($RCL) Stock Hub: Dividend Confirmed at $1.50, Refinancing Closed and the Q3 Margin Test • Updated Sep 21, 2026](https://www.merlintrader.com/royal-caribbean-stock-hub/): Stock Hub 2026 · Travel & Cruise Cruise demandCapital intensiveDividend confirmedPermitting risk NYSE: $RCL Royal Caribbean ($RCL) Stock Hub: Dividend Confirmed at $1.50, Refinancing Closed and the Q3 Margin Test • Updated Sep 21, 2026 The board declared a quarterly dividend of $1.50 a share on September 1, 2026, payable on October 8 to holders […]
- [Carnival Corporation ($CCL) Stock Hub: Third-Quarter Results Due September 29, After Twelve Straight Record Yield Quarters • Updated Sep 21, 2026](https://www.merlintrader.com/carnival-corporation-stock-hub/): Stock Hub 2026 · Travel & Cruise Largest cruise operatorInvestment gradeTwelve record yield quartersNo fuel hedging NYSE: $CCL Carnival Corporation ($CCL) Stock Hub: Third-Quarter Results Due September 29, After Twelve Straight Record Yield Quarters • Updated Sep 21, 2026 Carnival reports the third quarter of fiscal 2026 on the morning of September 29, 2026, with […]
- [United Airlines ($UAL) Stock Hub: The Starlink Seatback Expansion Adds Live Football With DISH • Updated Sep 21, 2026](https://www.merlintrader.com/united-airlines-stock-hub/): Stock Hub 2026 · Travel & Airlines Network carrierJuly guidanceCapital intensiveFuel risk Nasdaq: $UAL United Airlines ($UAL) Stock Hub: The Starlink Seatback Expansion Adds Live Football With DISH • Updated Sep 21, 2026 United said on September 17, 2026 that DISH will carry live football on its Starlink-equipped seatback screens, with more than 220 mainline […]
- [Delta Air Lines ($DAL) Stock Hub: Los Angeles Expansion and the September-Quarter Call Set for October 9 • Updated Sep 21, 2026](https://www.merlintrader.com/delta-air-lines-stock-hub/): Stock Hub 2026 · Travel & Airlines Network carrierPremium ticket mixRefinery economicsFuel and execution risk NYSE: $DAL Delta Air Lines ($DAL) Stock Hub: Los Angeles Expansion and the September-Quarter Call Set for October 9 • Updated Sep 21, 2026 Delta said on September 18, 2026 that it and its partners will fly more than 200 […]
- [American Airlines ($AAL) Stock Hub: SAF Commitments, DFW Expansion and Premium Fleet](https://www.merlintrader.com/american-airlines-stock-hub/): Stock Hub 2026 · Travel & Airlines Network carrierRecord revenueFuel exposedHigh leverage Nasdaq: $AAL American Airlines ($AAL) Stock Hub: SAF Commitments, DFW Expansion and Premium Fleet The September 22 SABA announcement names American Airlines as the physical offtaker and logistics partner for SAF associated with Infinium’s planned Project Atlas. This joins the September 18 DFW […]
- [Moderna ($MRNA): INTerpath-001 Phase 3 Presentation Scheduled for October 24 at ESMO](https://www.merlintrader.com/moderna-stock-hub/): Moderna's investment thesis changed materially on August 19, 2026. The pivotal INTerpath-001 study of individualized neoantigen therapy intismeran autogene plus Merck's KEYTRUDA achieved its reported Phase 3 efficacy objectives in high-risk resected melanoma. The result gives Moderna its strongest late-stage therapeutic validation outside infectious disease, while FDA approval of MFLUSIVA, a broader respiratory portfolio and billions of dollars in liquidity provide additional strategic depth. The remaining debate is no longer whether Moderna can produce a meaningful non-COVID late-stage signal. It is whether the company can convert that scientific validation into regulatory approvals, scalable personalized manufacturing, durable revenue and sustainable cash economics.
- [Amylyx Pharmaceuticals ($AMLX) Stock Hub 2026: LUCIDITY Hit Its Endpoint and a $500M Offering Followed — What Does the NDA Need Now?](https://www.merlintrader.com/amylyx-pharmaceuticals-stock-hub/): Amylyx has crossed the biggest clinical hurdle in its current story. Phase 3 LUCIDITY showed a 55% reduction versus placebo in the FDA-agreed composite rate of Level 2 and Level 3 hypoglycemic events, with p=0.000003 and all reported secondary endpoints met. The debate now moves from pivotal efficacy risk toward FDA execution, label scope, commercialization, pricing, reimbursement and whether avexitide can establish the first approved treatment franchise in post-bariatric hypoglycemia.
- [Eton Pharmaceuticals ($ETON) Stock Hub 2026: Q2 Growth, $145M Guidance and the Valuation Test](https://www.merlintrader.com/eton-pharmaceuticals-stock-hub/): Eton Pharmaceuticals stock hub updated August 15, 2026: Q2 revenue growth, raised $145M-plus guidance, eleven commercial products, pipeline, debt, dilution and valuation.
- [Americas Gold and Silver ($USAS) Stock Hub: Galena Discoveries and September 25 Events](https://www.merlintrader.com/americas-gold-and-silver-usas-stock-hub-2026/): Americas Gold and Silver stock hub: second quarter 2026 revenue of $46.3 million, the Galena No. 3 Shaft upgrade, the Crescent restart in Idaho, and $85 million of silver and gold delivery obligations settled in shares.
- [Unusual Machines ($UMAC): revenue up sevenfold and a $52 million acquisition](https://www.merlintrader.com/unusual-machines-umac-stock-hub/): UMAC Stock Hub updated August 20, 2026: Q2 growth, domestic drone components, tariffs, dilution and three SEC Form 144 notices covering 48,538 proposed insider-sale shares.
- [Lithium Americas Corp. ($LAC) Stock Hub 2026: Thacker Pass, The GM Partnership And The $2.23 Billion DOE Loan • Editorial review Sep 17, 2026](https://www.merlintrader.com/lithium-americas-lac-stock-hub/): Lithium Americas reported Q2 2026 on August 13: $1.28 billion of cash, $483.6 million of quarterly capex and a definitive capital estimate for Thacker Pass due by the end of September. Full hub on the DOE loan, the GM joint venture, the funding stack and every dated catalyst.
- [ARTL Stock Hub: ART27.13 obesity findings are preclinical, not human efficacy data](https://www.merlintrader.com/artelo-biosciences-stock-hub/): ARTL hub: Q2 2026 cash and burn, ART27.13 CAReS and DREAM glaucoma data, ART26.12 MAD, ART12.11, warrants, dilution, valuation, catalysts and risks.
- [Autolus ($AUTL) Stock Hub: Can AUCATZYL Growth Outrun Capital Costs?](https://www.merlintrader.com/autolus-therapeutics-stock-hub/): Evidence-first AUTL research hub covering the AUCATZYL launch, Q2 2026 gross margin, financing, clinical catalysts, valuation and key risks.
- [BioCardia ($BCDA) Stock Hub: Can Helix and Japan Advance Within the Funding Window?](https://www.merlintrader.com/biocardia-bcda-stock-hub/): BioCardia ($BCDA) stock hub: Japan's PMDA supports a Shonin submission and the FDA says CardiAMP HF II may support a Premarket Approval, while stockholders' equity sits $200,000 above the Nasdaq minimum with the ATM exhausted and a compliance deadline on October 7, 2026.
- [Spero Therapeutics ($SPRO) Stock Hub: Utebzi, SP001 and New Financing Capacity](https://www.merlintrader.com/spero-therapeutics-stock-hub/): SPRO hub covering Utebzi, GSK economics, SP001 human data, Q2 2026 cash, dilution, catalysts, valuation and falsifiable risks.
- [INOVIO Pharmaceuticals (Nasdaq: $INO) Stock Hub: FDA Inspections Complete Before the October 30 PDUFA](https://www.merlintrader.com/inovio-pharmaceuticals-stock-hub/): INOVIO ($INO) stock hub: INO-3107 faces an October 30, 2026 PDUFA date in recurrent respiratory papillomatosis, with accelerated approval eligibility unresolved, an approved competitor already in the indication, and about three quarters of cash.
- [Savara ($SVRA) Stock Hub: ERS Encore, November FDA Review and Conditional Funding](https://www.merlintrader.com/savara-svra-stock-hub-2026/): Savara has one asset and one date: the FDA target action date of November 22, 2026 for MOLBREEVI in autoimmune pulmonary alveolar proteinosis. Full stock hub: the IMPALA-2 data read precisely, the 2025 refuse-to-file and the three-month extension, $173.0 million of liquidity, the $150 million that opens only on approval, and a third of the float sold short.
- [Dermata Therapeutics ($DRMA) Stock Hub: Can Tome Turn Its Launch into Repeat Demand?](https://www.merlintrader.com/dermata-therapeutics-drma-stock-hub/): $DRMA Stock Hub: Tome launched August 25. Follow consumer adoption, the August financing, cash runway, warrants and the risks of Dermata’s skincare pivot.
- [Cardiff Oncology ($CRDF) Stock Hub: NMS Agreement Reached, Phase 3 Funding Still Open](https://www.merlintrader.com/cardiff-oncology-crdf-stock-hub-2026/): Cardiff Oncology ($CRDF) stock hub: the NMS licence dispute awaiting a ruling, the October 22 special meeting to double authorised shares, CRDF-004 data, cash, going concern and Nasdaq bid-price status, updated September 6, 2026.
- [PolyPid ($PYPD) Stock Hub: Priority Review Pulls the D-PLEX 100 Decision Forward to November 28](https://www.merlintrader.com/polypid-pypd-stock-hub/): A complete PYPD hub on D-PLEX100, SHIELD II, FDA Priority Review and the November 28, 2026 PDUFA, Azurity, Q2 2026 cash and dilution.
- [Biofrontera ($BFRI) Stock Hub: FDA Approves Ameluz for Superficial Basal Cell Carcinoma](https://www.merlintrader.com/biofrontera-bfri-stock-hub/): Biofrontera BFRI Stock Hub updated for Q2 2026: $12.0M revenue, 80% gross margin, near-breakeven adjusted EBITDA, September 28 sBCC PDUFA, RhodoLED XL risk and dilution.
- [Organigram (Nasdaq: $OGI) Stock Hub 2026: Q3 FY2026 Revenue Up 49% to C$105.8 Million, the Sanity Integration Accelerated and the Earnout Fixed at 85%](https://www.merlintrader.com/organigram-ogi-stock-hub-2026/): Organigram Global reported third quarter fiscal 2026 net revenue of C$105.8 million, up 49%, with adjusted EBITDA up 136% and a reported profit of C$105.5 million that is almost entirely a non-cash fair value gain. Full stock hub: the quarter, Sanity Group in Germany, Canadian market share, the British American Tobacco structure, cash down 86% and the guidance.
- [Legend Biotech ($LEGN) Stock Hub 2026: CARVYKTI Grew 50% and the Quarter Turned Profitable — What Does LB2501 Still Have to Prove?](https://www.merlintrader.com/legend-biotech-stock-hub/): Legend Biotech ($LEGN) stock hub: CARVYKTI Q2 sales, profitability, LB2501 data, pipeline, cash, dilution, catalysts, valuation and risks.
- [$RIOT Riot Platforms Stock Hub 2026: The 191 MW Rockdale Lease And The AI Data Centre Expansion • Editorial review Sep 17, 2026](https://www.merlintrader.com/riot-platforms-riot-stock-hub/): Riot Platforms signed a twenty-year, 191 MW data centre lease at Rockdale worth approximately $9.1 billion with an unnamed frontier AI lab. What the filings say about the terms, the financing, the bitcoin treasury funding the buildout and the risks between here and first rent in December 2027.
- [AC Immune ($ACIU) Stock Hub 2026: First NLRP3 Data, VacSYn Readout Ahead and Funding Into Q4 2027](https://www.merlintrader.com/ac-immune-aciu-stock-hub-2026/): The FDA granted Fast Track designation and cleared the IND for AC Immune's Parkinson's disease vaccine ACI-7104 on August 11, 2026, opening the Phase 2 VacSYn trial to United States sites. Full stock hub: the interim data read precisely, the pipeline, the partner agreements, CHF 75.4 million of cash and a runway into the fourth quarter of 2027.
- [Rigel Pharmaceuticals ($RIGL) Stock Hub: September Conferences, VEPPANU Launch and R289](https://www.merlintrader.com/rigel-pharmaceuticals-stock-hub/): Complete RIGL stock hub covering Rigel Pharmaceuticals Q2 2026 results, TAVALISSE, REZLIDHIA, GAVRETO, the VEPPANU launch, R289, cash, debt, dilution, valuation, catalysts and risks.
- [Axsome Therapeutics ($AXSM): Shared Goals Survey Adds Caregiver Context](https://www.merlintrader.com/axsome-therapeutics-axsm-stock-hub-2026/): Axsome Therapeutics reported $218.4 million of second quarter 2026 revenue against $208.1 million of selling expense and a $51.3 million net loss. Full stock hub: the Alzheimer's disease agitation launch, financials, pipeline, capital structure, insider activity, retail sentiment and every dated catalyst.
- [URGN Stock Hub: ZUSDURI, UGN-103 and IntraGel](https://www.merlintrader.com/urogen-pharma-urgn-stock-hub/): The launch is working and the numbers prove it. The open question is who captures the result, because the equity sits behind a US$200 million term loan and a revenue interest sold to a fund.
- [Cronos Group ($CRON) Stock Hub: CanAdelaar Long-Stop Date Extended to October 15](https://www.merlintrader.com/cronos-group-stock-hub/): Cronos has moved beyond the old cannabis-sector template of shrinking revenue, perpetual dilution and distant profitability. The company delivered record second-quarter revenue, gross profit and adjusted EBITDA, supported by Canadian category leadership, a record Israeli medical franchise and expanding German demand. Its unusually large cash and investment reserve changes the risk profile, while the pending CanAdelaar acquisition and a renewed Israeli anti-dumping investigation create the next major upside and downside branches.
- [SNDL ($SNDL) Stock Hub 2026: EU-GMP Audit Cleared at Atholville, Parallel Completed and Retail Scale in View](https://www.merlintrader.com/sndl-stock-hub/): SNDL is no longer a simple Canadian cultivation story. It combines one of Canada’s largest cannabis-retail networks, a large private-liquor platform, branded cultivation and manufacturing, a substantial investment portfolio, aggressive share repurchases and a complicated route toward U.S. medical-cannabis consolidation through Parallel. The core debate is whether that asset base can finally produce durable per-share cash flow while operating margins remain under pressure.
- [Silence Therapeutics ($SLN) Stock Hub: SANRECO Follow-Up, Completed Offering and Phase 3 Plans](https://www.merlintrader.com/silence-therapeutics-sln-stock-hub/): SLN hub: positive SANRECO Phase 2 data, Q2 liquidity, the $175M ADS offering, dilution math and the planned divesiran Phase 3 start in 1H27.
- [Telix Pharmaceuticals ($TLX): Proposed ITM Acquisition Expands the Radiopharma Strategy](https://www.merlintrader.com/telix-pharmaceuticals-tlx-stock-hub/): Telix already sells more than US$800 million of radiopharmaceutical product a year. What is still open is the manufacturing compliance record behind it, an unresolved Complete Response Letter, an SEC subpoena and a cash line that has not been disclosed since December.
- [USA Rare Earth ($USAR) Stock Hub: The Pasqal Quantum Partnership And The Blacksburg Magnet Plant • Editorial review Sep 17, 2026](https://www.merlintrader.com/usa-rare-earth-usar-stock-hub/): USA Rare Earth stock hub: verified numbers on the Stillwater magnet ramp, the Round Top deposit, the $1.6 billion Department of Commerce package, and the two dated catalysts ahead - Q2 results on August 10 and the August 28 vote on issuing 126.8 million new shares.
- [Intellia Therapeutics ($NTLA) Stock Hub: FDA accepts lonvo-z BLA with Priority Review; March 10, 2027 PDUFA](https://www.merlintrader.com/intellia-therapeutics-ntla-stock-hub/): Intellia Therapeutics ($NTLA) stock hub: the OrbiMed loan of up to $400 million, the lonvo-z rolling BLA, HAELO data, cash, dilution, short interest and catalysts, updated September 6, 2026.
- [SoundHound AI ($SOUN): record revenue and the LivePerson merger closed](https://www.merlintrader.com/soundhound-ai-stock-hub/): SoundHound AI: LivePerson acquired September 4, 2026, John Collins appointed CFO, actual closing terms and integration and dilution risks.
- [Kratos ($KTOS): record revenue, raised guide, F143 ignition](https://www.merlintrader.com/kratos-defense-ktos-stock-hub/): Kratos ($KTOS) Stock Hub updated September 1, 2026: $20M+ mobile SATCOM contract in Asia, $35M hardware award, Q2 growth, backlog, cash use, dilution and execution risks.
- [SpaceX ($SPCX): revenue rose 92% and a $60 billion acquisition closed](https://www.merlintrader.com/spacex-stock-hub/): SpaceX ($SPCX) stock hub, updated September 1, 2026: Starshield AI's Grok for Government launched on GenAI.mil at IL5; NASA moved Crew-13 after a Dragon oxidizer leak; plus Q2 financials, Starlink, backlog and the lock-up calendar.
- [Senseonics ($SENS) Stock Hub: Beta Bionics Partnership, iLet Integration Targeted for Q4](https://www.merlintrader.com/senseonics-holdings-stock-hub/): Management will hold the conference call at 4:30 p.m. ET. This is the first major financial checkpoint after the ADA 2026 data, the Welldoc app partnership, the European launch, the $92 million equity financing and the expansion of the Hercules debt facility.
- [Merlintrader Educational Library: the complete map of the guides](https://www.merlintrader.com/educational/): Merlintrader Learning Library Merlintrader Educational Library The guides that sit underneath the reports: how an FDA date is read, how a company with no revenue is valued, what happens to the capital when a raise arrives, what moves a price with no news at all, and which mistakes repeat every cycle. Search by word or […]
- [PDS Biotech ($PDSB) Stock Hub: $11.3M PIPE Closing and Soon-Shiong Board Appointment](https://www.merlintrader.com/pds-biotechnology-stock-hub/): PDS Biotechnology discontinued VERSATILE-003, stopped internal investment in PDS0101 and made PDS0301 its lead program. This updated hub examines the mCRC data, the August 13 Q2 catalyst, cash, financing, dilution and Nasdaq risk.
- [Zymeworks ($ZYME): the doublet clears overall survival too, one week after the FDA approval that earned $250 million](https://www.merlintrader.com/zymeworks-stock-hub/): Zymeworks ($ZYME) stock hub: on August 25, 2026 the FDA approved two Ziihera regimens in first-line HER2-positive gastroesophageal adenocarcinoma and Zymeworks earned the $250 million Jazz milestone. Label, HERIZON-GEA-01 data, cash, the Theravance deal and every catalyst. Educational research, not investment advice.
- [Karyopharm Therapeutics ($KPTI) Stock Hub: Can the October 15 Forbearance Window Buy Time for a Financing Solution? • Updated Sep 12, 2026](https://www.merlintrader.com/karyopharm-therapeutics-stock-hub/): Q2 2026 confirmed a resilient XPOVIO franchise but made the financing risk urgent: $65.1 million of cash and investments, runway only into September, $15.8 million of principal and about $10.1 million of cash interest due in the same month, while the myelofibrosis sNDA remains planned for August.
- [Weekly Market Pulse: Fed Hike, QQQ Resilience and Narrow Breadth | September 14–18, 2026](https://www.merlintrader.com/weekly-market-pulse/): Finviz weekly data through September 18: SPY −0.34%, QQQ +0.92%, Fed at 3.75–4.00%, sector rotation, earnings and the next biotech dates.
- [Definium Therapeutics ($DFTX) Stock Hub: Panorama Positive, Next Comes the FDA Filing Path](https://www.merlintrader.com/definium-therapeutics-stock-hub/): DFTX Stock Hub: positive Voyage data, September Panorama readout, Q2 cash and dilution, clinical risks and the path toward a potential DT120 filing.
- [Hims & Hers Health $HIMS Stock Hub: Digital Health, GLP-1s, Peptides and Global Expansion](https://www.merlintrader.com/hims-hers-health-stock-hub/): A complete evergreen research hub on Hims & Hers: the consumer-health platform model, telemedicine, online pharmacy, compounded and branded medicines, GLP-1 strategy, peptide optionality, Eucalyptus integration, international expansion, financials, debt, dilution, regulatory risk, competition, valuation and bull/base/bear scenarios.
- [C3.ai ($AI): free cash flow turns positive and cash rises to $651 million](https://www.merlintrader.com/c3-ai-stock-hub/): C3.ai ($AI) Stock Hub updated August 20, 2026: fiscal Q1 2027 results officially scheduled for September 2 at 5:00 p.m. ET, revenue reset, cash burn, dilution and federal exposure.
- [Virgin Galactic ($SPCE): First Commercial Flight Moves to February 2027](https://www.merlintrader.com/virgin-galactic-spce-stock-hub-2026/): Virgin Galactic Q2 2026 Hub update: $286 million of cash and securities, $90.7 million of negative free cash flow, $134 million of ATM issuance, an oversubscribed $750,000 ticket tranche and the first commercial flight moved to February 2027.
- [Bloom Energy ($BE): Indelible-Bloom Selected for Conditional Army Energy Leases](https://www.merlintrader.com/bloom-energy-stock-hub/): A complete post-earnings investor guide to Bloom Energy: record Q2 2026 results, raised guidance, AI data-center power demand, Oracle and Brookfield structures, customer concentration, cash conversion, valuation, technical levels, catalysts and risks.
- [Insider Trading Weekly: CRBG Leads Buys, FANG Leads Sales | September 14–18, 2026](https://www.merlintrader.com/insider-trading-weekly/): September 14–18 insider transactions from Finviz, reconciled to SEC Form 4: CRBG, USO, FANG and AUR, with duplicates and currency traps identified.
- [Pharvaris ($PHVS): September 21 Form 4s Update the Insider Transaction Record](https://www.merlintrader.com/pharvaris-stock-hub/): A complete investor guide to Pharvaris, its oral bradykinin B2 receptor antagonist deucrictibant, the imminent CHAPTER-3 Phase 3 prophylaxis readout, the accepted U.S. NDA for on-demand treatment, the April 23, 2027 PDUFA date, commercial competition, cash runway, dilution and the evidence that could confirm or break the investment thesis.
- [EyePoint ($EYPT) Stock Hub 2026: What Does LUCIA Have to Show After LUGANO, and Who Bought in August?](https://www.merlintrader.com/eyepoint-stock-hub/): Updated August 15, 2026: EyePoint's Q2 filing confirms $180.5 million of liquidity, accelerating burn and ATM dilution ahead of the LUGANO and LUCIA Phase 3 wet AMD readouts.

## Optional

- [Agent (MCP protocol)](websites-agents.hostinger.com/www.merlintrader.com/mcp)

[comment]: # (Generated by Hostinger Tools Plugin)